Bladder Disease

Categories: Blood diseases, Nephrological diseases

Aliases & Classifications for Bladder Disease

MalaCards integrated aliases for Bladder Disease:

Name: Bladder Disease 12 15 38 17
Urinary Bladder Diseases 44 72
Bladder Diseases 55 43
Urinary Bladder Disease 12


External Ids:

Disease Ontology 12 DOID:365
ICD9CM 35 596.9
MeSH 44 D001745
NCIt 50 C2900
SNOMED-CT 68 42643001
UMLS 72 C0005686

Summaries for Bladder Disease

MedlinePlus : 43 The bladder is a hollow organ in your lower abdomen that stores urine. Many conditions can affect your bladder. Some common ones are Cystitis - inflammation of the bladder, often from an infection Urinary incontinence - loss of bladder control Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination Bladder cancer Doctors diagnose bladder diseases using different tests. These include urine tests, x-rays, and an examination of the bladder wall with a scope called a cystoscope. Treatment depends on the cause of the problem. It may include medicines and, in severe cases, surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Bladder Disease, also known as urinary bladder diseases, is related to cystitis and interstitial cystitis, and has symptoms including bladder fullness sensation An important gene associated with Bladder Disease is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Pathways in cancer and MicroRNAs in cancer. The drugs Mirabegron and Rocuronium have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and spinal cord, and related phenotypes are homeostasis/metabolism and neoplasm

Disease Ontology : 12 A urinary system disease that is located in the bladder.

Wikipedia : 75 Urinary bladder disease includes urinary bladder inflammation such as cystitis, bladder rupture and... more...

Related Diseases for Bladder Disease

Diseases related to Bladder Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
# Related Disease Score Top Affiliating Genes
1 cystitis 33.1 UPK3A TRPV1 HBEGF
2 interstitial cystitis 31.0 UPK3A TRPV1 HBEGF CDH1
3 transitional cell carcinoma 30.5 UPK3A UPK2 TP53 FGFR3 CDH1
4 bladder urothelial carcinoma 30.2 UPK3A TP53 FGFR3 CDH1
5 chronic cystitis 29.9 UPK3A NUMA1
6 bladder cancer 29.4 UPK3A UPK2 TP53 TERT NUMA1 MIR145
7 gallbladder disease 11.4
8 diphyllobothriasis 10.9
9 urinary tract papillary transitional cell benign neoplasm 10.8 TP53 TERT FGFR3
10 bladder papillary transitional cell neoplasm 10.8 TP53 TERT FGFR3
11 cerebral convexity meningioma 10.8 TP53 CDH1
12 non-invasive bladder papillary urothelial neoplasm 10.7 UPK3A TP53 FGFR3
13 bladder squamous cell carcinoma 10.7 UPK2 TP53
14 laryngeal squamous cell carcinoma 10.7 TP53 TERT CDH1
15 bladder carcinoma in situ 10.7 UPK2 TP53 ELAVL3
16 laryngeal disease 10.7 TP53 GSTM1 CDH1
17 stomach disease 10.7 TRPV1 TP53 CDH1
18 male reproductive system disease 10.7 TRPV1 TP53 CDH1
19 pharynx cancer 10.7 TP53 GSTM1 CDH1
20 reproductive system disease 10.7 TRPV1 TP53 CDH1
21 female reproductive system disease 10.7 TRPV1 TP53 CDH1
22 invasive bladder transitional cell carcinoma 10.7 UPK3A TP53
23 oral cancer 10.7 TP53 GSTM1 CDH1
24 intestinal disease 10.7 TRPV1 TP53 CDH1
25 diffuse gastric cancer 10.7 MIR103A1 GSTM1 CDH1
26 gastrointestinal system disease 10.6 TRPV1 TP53 HBEGF CDH1
27 testicular germ cell tumor 10.6 TP53 MIR145 FGFR3
28 leukemia, chronic lymphocytic 2 10.6 TP53 MIR34A MIR145
29 ureteral disease 10.6 UPK3A SLC7A9 SLC3A1 CDH1
30 respiratory system cancer 10.6 TP53 TERT GSTM1 CDH1
31 respiratory system disease 10.6 TRPV1 TP53 CDH1
32 oral cavity cancer 10.6 TP53 GSTM1 CDH1
33 adamantinoma of long bones 10.6 TP53 TERT GSTM1 CDH1
34 gastric diffuse adenocarcinoma 10.6 UPK2 CDH1
35 renal hypodysplasia/aplasia 3 10.6 UPK3A FGFR3
36 larynx cancer 10.6 TP53 TERT GSTM1
37 lung squamous cell carcinoma 10.6 TP53 GSTM1 FGFR3 CDH1
38 suppression of tumorigenicity 12 10.5 UPK3A TP53 CDH1
39 vulvar disease 10.5 UPK3A TP53
40 squamous cell carcinoma, head and neck 10.5 TP53 GSTM1 FGFR3 CDH1
41 large intestine cancer 10.5 TP53 TERT GSTM1 CDH1
42 cervical cancer 10.5 TP53 TERT GSTM1 FGFR3 CDH1
43 nasopharyngeal carcinoma 10.4 TP53 TERT GSTM1 CDH1
44 sarcomatoid renal cell carcinoma 10.4 TP53 CDH1
45 esophageal cancer 10.3 TP53 TERT MIR34A GSTM1 CDH1
46 gastric cancer 10.3 TP53 TERT MIR34A MIR145 GSTM1 CDH1
47 lung cancer susceptibility 3 10.2 TP53 TERT FGFR3 CDH1
48 neurogenic bladder 10.2
49 cholecystitis 10.0
50 cholelithiasis 9.9

Comorbidity relations with Bladder Disease via Phenotypic Disease Network (PDN):

Acute Cystitis Bladder Neck Obstruction
Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Bladder Disease:

Diseases related to Bladder Disease

Symptoms & Phenotypes for Bladder Disease

UMLS symptoms related to Bladder Disease:

bladder fullness sensation

MGI Mouse Phenotypes related to Bladder Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 CDH1 CHRM3 ELAVL3 ERCC6 FGFR3 HBEGF
2 neoplasm MP:0002006 9.43 CDH1 ERCC6 FGFR3 TERT TP53 TRPV1
3 renal/urinary system MP:0005367 9.28 CHRM3 FGFR3 IDO1 SLC3A1 SLC7A9 TP53

Drugs & Therapeutics for Bladder Disease

Drugs for Bladder Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Mirabegron Approved Phase 4 223673-61-8 9865528
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
3 Muscarinic Antagonists Phase 4
4 Neurotransmitter Agents Phase 4
5 Adrenergic Agonists Phase 4
6 Adrenergic beta-Agonists Phase 4
7 Cholinergic Agents Phase 4
8 Solifenacin succinate Phase 4 242478-38-2
9 Adrenergic beta-3 Receptor Agonists Phase 4
10 Cholinergic Antagonists Phase 4
11 Adrenergic Agents Phase 4
12 Neuromuscular Agents Phase 4
13 Neuromuscular Nondepolarizing Agents Phase 4
14 Neuromuscular Blocking Agents Phase 4
15 Bromides Phase 4
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
tannic acid Approved Phase 3 1401-55-4
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
Amitriptyline Approved Phase 3 50-48-6 2160
Perphenazine Approved Phase 3 58-39-9 4748
Adalimumab Approved Phase 3 331731-18-1 16219006
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
Valrubicin Approved Phase 3 56124-62-0 41744
26 Tolterodine tartrate Phase 3 124937-52-6
27 abobotulinumtoxinA Phase 3
28 Acetylcholine Release Inhibitors Phase 3
29 Botulinum Toxins Phase 3
30 Botulinum Toxins, Type A Phase 3
31 Mitogens Phase 3
32 Analgesics Phase 3
33 Antidepressive Agents Phase 3
34 Amitriptyline, perphenazine drug combination Phase 3
35 Tranquilizing Agents Phase 3
36 Analgesics, Non-Narcotic Phase 3
37 Neurotransmitter Uptake Inhibitors Phase 3
38 Psychotropic Drugs Phase 3
39 Antidepressive Agents, Tricyclic Phase 3
40 Antipsychotic Agents Phase 3
41 Anti-Inflammatory Agents Phase 3
42 Antirheumatic Agents Phase 3
43 Peripheral Nervous System Agents Phase 3
44 Parasympatholytics Phase 3
45 Autonomic Agents Phase 3
46 Anti-Infective Agents Phase 3
47 Renal Agents Phase 3
48 Mandelic Acids Phase 3
49 Anti-Infective Agents, Urinary Phase 3
50 Topoisomerase Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
2 The Effect of Deep Neuromuscular Blockade on Postoperative Shoulder Tip Pain After Laparoscopic Cholecystectomy Completed NCT02036827 Phase 4 Rocuronium
3 Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
4 A Double-Blind, Randomized Study of Puncturing Versus Non-Puncturing Acupuncture for the Treatment of Interstitial Cystitis Symptoms Unknown status NCT00094874 Phase 3
5 A Double-Blind, Randomized Study of the Safety and Efficacy of OnabotulinumtoxinA (OnaBoNT-A) Versus Oral Oxybutynin in Spinal Cord Injured Patients With Neurogenic Detrusor Overactivity (Protocol Number 11-09-10-04) Unknown status NCT01050114 Phase 3 onaBoNT-A;Oxybutynin ER
6 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
7 A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder Completed NCT01972841 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin succinate;Placebo to match mirabegron
8 A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy Completed NCT01638000 Phase 3 Mirabegron;Solifenacin succinate
9 A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms Completed NCT01908829 Phase 3 mirabegron 25 mg;mirabegron 50 mg;solifenacin 5 mg;solifenacin 10 mg;mirabegron 25 mg matching placebo;mirabegron 50 mg matching placebo;solifenacin 5 mg matching placebo;solifenacin 10 mg matching placebo
10 A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder Completed NCT02045862 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin;Placebo to match mirabegron
11 A Randomized Multicenter Clinical Trial to Evaluate the Efficacy of Amitriptyline for the Treatment of Painful Bladder Syndrome (PBS) in Newly Diagnosed Patients Completed NCT00124306 Phase 3 Amitriptyline
12 An Investigator Initiated, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Humira® (Adalimumab) For The Treatment of Interstitial Cystitis(IC) Completed NCT01295814 Phase 3 Adalimumab
13 Oxybutynin for Post-surgical Bladder Pain and Urgency Recruiting NCT03952299 Phase 3 Oxybutynin Transdermal Patch;Oral Oxybutynin
14 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
16 A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer Terminated NCT01200992 Phase 3
17 A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC) Withdrawn NCT02254915 Phase 3 Bacillus Calmette-Guérin
18 A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin Completed NCT00256542 Phase 2 Alkalinized Lidocaine-Heparin
19 A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder. Completed NCT01340027 Phase 2 Mirabegron;Solifenacin succinate;Placebo
20 A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis Completed NCT01613586 Phase 2 ASP3652;Placebo
21 Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients Completed NCT02307487 Phase 2 120 mg MMC in 90ml gel;140 mg MMC in 90ml gel;160 mg MMC in 90ml gel;120 mg MMC in 60ml gel;140 mg MMC in 60ml gel;160 mg MMC in 60ml gel
22 A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Recruiting NCT03081858 Phase 1, Phase 2 TSD-001
23 A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy Recruiting NCT03123055 Phase 1, Phase 2 B-701;Pembrolizumab
24 A Phase 2 Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder Recruiting NCT02901548 Phase 2 Durvalumab
25 A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy Active, not recruiting NCT02401542 Phase 1, Phase 2 Vofatamab;Docetaxel;Placebo
26 A Multi-centre Randomized, Placebo-controlled Trial of Mirabegron, a New beta3-adrenergic Receptor Agonist on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease Enrolling by invitation NCT02599480 Phase 2 mirabegron
27 A Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety and Tolerability of SAF312 in Subjects With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Who Are Inadequately Managed by Antimuscarinic Therapy Terminated NCT01598103 Phase 2 SAF312;Placebo to SAF312
28 A Randomized Controlled Trial to Evaluate the Efficacy and Tolerability of Intravesical Cocktail and Comparison With Intravesical Dimethyl Sulfoxide (DMSO) for the Treatment of Painful Bladder Syndrome Including Interstitial Cystitis (PBS/IC) Terminated NCT00317070 Phase 2 dimethyl sulfoxide;IC Cocktail
29 A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome Terminated NCT01060254 Phase 2 Placebo;JNJ-42160443
30 A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors Completed NCT00753415 Phase 1
31 A Phase I/1b Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Completed NCT02300610 Phase 1 Enzalutamide;Cisplatin;Gemcitabine
32 Three-dimensional High-definition (3DHD) Laparoscopy Versus Two-dimensional High-definition (2DHD) Laparoscopy in Cholecystectomy: a Clinical Controlled Randomized Double Blinded Trial. Unknown status NCT02396927
33 Prospective Multicenter Human Randomized Controlled Evaluation of NOTES® Cholecystectomy Unknown status NCT01171027
34 A Multi Center Study to Obtain Bladder Tissue Specimens From Subjects Undergoing Transurethral Resection of Bladder Tumor (TURBT) or Other Transurethral Biopsy Procedures Completed NCT00615043
35 Bladder Endometriosis: Evaluation in MRI of the Involvement of the Posterior Inferior Wall Completed NCT03906760
36 A Prospective, Non-interventional, Registry Study of Patients Initiating a Course of DrugTherapy for Overactive Bladder (OAB) Completed NCT02386072 mirabegron;antimuscarinic medication
37 Non-Interventional Study Assessing Quality of Life, Treatment Satisfaction, Resource Utilisation, and Persistence With Treatment in Overactive Bladder (OAB) Patients Prescribed Betmiga® - A Multicenter Non-interventional Post Authorisation Study (PAS) Completed NCT02320773 Betmiga®
38 Biomechanical Assessment of Level Gait in Patient's Status Post Bladder Exstrophy Completed NCT00863070
39 Does Three-Dimensional Laparoscopy Provide Significant Advantages for Patients and Surgeons? A Randomised Controlled Trial Investigating Operating Time and Surgical Errors With 3D vs 2D Visual Systems in Laparoscopic Cholecystectomies. Completed NCT01930344
40 Evaluation of the Clinical Response of Mitomycin-C (MMC) Embedded in Hydrogel (TC-3) in Comparison to Mitomycin C in Saline, When Administered Intravesically, Pre-TURBT in Non Muscle Invasive Bladder Cancer (NMIBC) Patients. Muscle Invasive Bladder Cancer (NMIBC) Patients Completed NCT02891460
41 Heart Rate Variability in Patients With Neurogenic Detrusor Overactivity Before and After Botulinum Neurotoxin Type A Intradetrusor Injections Completed NCT01337024
42 Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Completed NCT01803295
43 Prospective Comparative Multicenter Study on the Medico-economical Impact of the Brindley Technique in the Management of Neurogenic Bladder in Patients With Injured Spinal Cord Completed NCT00221767
44 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country. Completed NCT00210249
45 Effect of Pelvic Floor Muscle Training (PFMT) in Prevention and Treatment of Female Pelvic Organ Prolapse (POP). Completed NCT00271297
46 A Randomized Trial of Single-Operator Ultrasound-Guided vs. Standard-of-Care IV Placement by Emergency Nurses Completed NCT01439113
47 Village Surveys of Morbidity Due to S. Haematobium for 1U01AI4547 Urinary Schistosomiasis-Determinants of Infection and Disease Completed NCT00138450
48 The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation Recruiting NCT03591367
49 A Randomized Control Trial of a Modified Cystoscopy Method to Reduce Pain Perception Recruiting NCT03257293
50 Investigation of Falls and Balance of Patients With Parkinson's Disease With Urinary Disturbance Recruiting NCT03845725

Search NIH Clinical Center for Bladder Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Acetic Acid
Neostigmine bromide
Neostigmine Methylsulfate
Propantheline Bromide
tolterodine tartrate

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Disease:
Neo-Urinary Conduit, smooth muscle cell 3D culture for bladder diseases
Embryonic/Adult Cultured Cells Related to Bladder Disease:
Neo-Urinary Conduit PMIDs: 22136657

Cochrane evidence based reviews: urinary bladder diseases

Genetic Tests for Bladder Disease

Anatomical Context for Bladder Disease

MalaCards organs/tissues related to Bladder Disease:

Testes, Kidney, Spinal Cord, Heart, Smooth Muscle, Prostate, Liver

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Disease:


Publications for Bladder Disease

Articles related to Bladder Disease:

(show top 50) (show all 619)
# Title Authors PMID Year
Bladder Augmentation (Enterocystoplasty): the Current State of a Historic Operation. 17
31342172 2019
Surgical treatment for pelvic lipomatosis using a bladder-sparing technique: A STROBE-compliant study. 17
31261563 2019
Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB). 17
31098731 2019
Differentiation potential of urothelium from patients with benign bladder dysfunction. 9 38
17537219 2007
Concentrations of specific epithelial growth factors in the urine of interstitial cystitis patients and controls. 9 38
9334654 1997
Metastatic plasmacytoid bladder cancer causing malignant priapism. 38
31266754 2019
Augmentation Cystoplasty of Diseased Porcine Bladders with Bi-Layer Silk Fibroin Grafts. 38
30191762 2019
Hypoxic changes to the urothelium as a bystander of end-stage bladder disease. 38
30862459 2019
NF-κB and GATA-Binding Factor 6 Repress Transcription of Caveolins in Bladder Smooth Muscle Hypertrophy. 38
30707892 2019
Chronic Lower Urinary Tract Signs in Cats: Current Understanding of Pathophysiology and Management. 38
30736893 2019
Necessity of performing voiding cystourethrography for children with unilateral multicystic dysplastic kidney. 38
30255447 2019
Leiomyoma of the Retzius space in a male patient: A case report and a diagnostic approach to Retzius space diseases. 38
30374998 2019
Spontaneous cholecystopleural fistula leading to biliothorax and sepsis in a cat. 38
30792876 2019
Differentiation of Urothelium from Mouse Embryonic Stem Cells in Chemically Defined Conditions. 38
31273737 2019
The Impact of Individual and Parental American Indian Boarding School Attendance on Chronic Physical Health of Northern Plains Tribes. 38
30431464 2019
Tissue Engineering in Pediatric Bladder Reconstruction-The Road to Success. 38
30984717 2019
A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome. 38
30072210 2018
Normal reference values for bladder wall thickness on CT in a healthy population. 38
29392368 2018
Gall bladder mucoceles in Border terriers. 38
30079451 2018
Therapeutic exploitation of IPSE, a urogenital parasite-derived host modulatory protein, for chemotherapy-induced hemorrhagic cystitis. 38
29613835 2018
Bladder and Ureteral Dysfunction Leading to Hydronephrosis and Hydroureteronephrosis in Adults. 38
29287975 2018
Characterization of voiding function and structural bladder changes in a rat model of neurogenic underactive bladder disease. 38
30105760 2018
Contrast-enhanced ultrasound complements two-dimensional ultrasonography in diagnosing gallbladder diseases in dogs. 38
29393556 2018
Underlying Chronic Disease, Medication Use, History of Running Injuries and Being a More Experienced Runner Are Independent Factors Associated With Exercise-Associated Muscle Cramping: A Cross-Sectional Study in 15778 Distance Runners. 38
28901963 2018
Bladder Leiomyosarcoma 25 Years after Treatment with Cyclophosphamide in Patient with History of Retinoblastoma. 38
26675030 2018
In Vitro Differentiation and Propagation of Urothelium from Pluripotent Stem Cell Lines. 38
28889383 2018
Asymptomatic solitary bladder plasmocytoma: A case report and literature review. 38
29390408 2017
Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. 38
28901968 2017
Emergency Department Utilization in Patients With Neurogenic Bladder: Contemporary Burden and National Trends in Prevalence, Inpatient Admission, and Associated Charges, 2006-2011. 38
28755964 2017
Antiproliferative factor (APF) binds specifically to sites within the cytoskeleton-associated protein 4 (CKAP4) extracellular domain. 38
28893174 2017
Cystic duct pressures after ligation with a novel absorbable device in an ex vivo caprine cholecystectomy model. 38
28725113 2017
Management of Neurogenic Bladder. 38
28553689 2017
Long-term Outcomes of Augmentation Enterocystoplasty in Patients With End-Stage Bladder Diseases: A Single-Institute Experience Involving 102 Patients. 38
28673062 2017
Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal study. 38
28645973 2017
Primary amyloidosis of the bladder; a mimicker of bladder cancer. 38
28646945 2017
Urinary excretion of EGF and MCP-1 in children with vesicoureteral reflux. 38
28191787 2017
Study on the Relation between Colorectal Cancer and Gall Bladder Disease. 38
28511430 2017
Cigarette smoke-induced urothelial cell damage: potential role of platelet-activating factor. 38
28270596 2017
Is mini-laparoscopic cholecystectomy any better than the gold standard?: A comparative study. 38
27251827 2017
Agenesis of gall bladder in laparoscopic cholecystectomy-A case report. 38
28802164 2017
Prevalence of Lower Urinary Tract Symptoms Among Individuals Aged 50 Years and Over and Its Effect on the Quality of Life in a Semi-Rural Area of Western Turkey. 38
28120441 2017
Fiber type-specific afferent nerve activity induced by transient contractions of rat bladder smooth muscle in pathological states. 38
29267380 2017
A microRNA biomarker panel for the non-invasive detection of bladder cancer. 38
27863434 2016
Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease. 38
27915472 2016
Translational Research for Pediatric Lower Urinary Tract Dysfunction. 38
27915476 2016
Single incision laparoscopic cholecystectomy in geriatric patients. 38
27663087 2016
Perioperative Complications and Outcome of Laparoscopic Cholecystectomy in 20 Dogs. 38
27503575 2016
Therapeutic Potential of Human Chorionic Gonadotropin Against Painful Bladder Syndrome/Interstitial Cystitis. 38
27004802 2016
Stem Cells in Functional Bladder Engineering. 38
27781020 2016
Risk of malignancy after augmentation cystoplasty: A systematic review. 38
25867054 2016

Variations for Bladder Disease

Expression for Bladder Disease

Search GEO for disease gene expression data for Bladder Disease.

Pathways for Bladder Disease

Pathways related to Bladder Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.28 TP53 TERT GSTM1 FGFR3 CDH1
2 11.92 TP53 MIR34A MIR199A1 MIR145 MIR103A1 FGFR3
4 10.37 MIR199A1 MIR145

GO Terms for Bladder Disease

Cellular components related to Bladder Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.17 UPK2 TRPV1 SLC7A9 SLC3A1 HBEGF FGFR3

Biological processes related to Bladder Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to hypoxia GO:0071456 9.5 TP53 TERT MIR34A
2 positive regulation of connective tissue replacement GO:1905205 9.16 MIR34A MIR199A1
3 L-alpha-amino acid transmembrane transport GO:1902475 8.96 SLC7A9
4 replicative senescence GO:0090399 8.96 TP53 TERT
5 L-cystine transport GO:0015811 8.62 SLC7A9 SLC3A1

Molecular functions related to Bladder Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein N-terminus binding GO:0047485 9.33 TP53 TERT ERCC6
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.26 MIR34A MIR199A1 MIR145 MIR103A1
3 L-cystine transmembrane transporter activity GO:0015184 8.62 SLC7A9 SLC3A1

Sources for Bladder Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....